Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) is a central nervous system disorder characterized by the presence of neurofibrillary tangles, neuritic plaques and dystrophic neurones in susceptible areas of the brain. Few options for treatment of AD symptomatology are available. We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel trial consisting of a 90 day treatment period followed by a 30 day single blind placebo administration and by an optional long term period of treatment up to a year with idebenone in open fashion. Ninety two patients entered the study and nine of them dropped out before the first control. Treatment with idebenone was found effective on memory, attention, and orientation and in slowing down the natural progressive worsening of the disease. The most common side effects associated with this treatment were insomnia, gastralgia, nausea, and anxiety. However, all adverse effects were of mild intensity and did not require specific therapies.

What this study adds

Evidence grade: High

This is a trial. This trial reported that idebenone was effective on memory, attention and orientation and slowed worsening in people with Alzheimer disease, with mild side effects. It is an older study of a symptomatic treatment, not a cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bergamasco, B., Scarzella, L., & La Commare, P. (1994). Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Functional neurology.

Vancouver

Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Functional neurology. 1994. PMID: 7988944.

BibTeX

@article{bergamasco1994-7988944,
  author  = {Bergamasco, B. and Scarzella, L. and La Commare, P.},
  title   = {{Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type}},
  journal = {Functional neurology},
  year    = {1994},
  pmid    = {7988944}
}

Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This trial reported that idebenone was effective on memory, attention and orientation and slowed worsening in people with Alzheimer disease, with mild side effects. It is an older study of a symptomatic treatment, not a cure or prevention.

Study details

How this study scored 54/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 4 of 7; Citations per year 1 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 50 of the 92 points it could be judged on, which is 54 of 100. Total 54 of 100.50 of the 92 points we could judge = 54 of 100

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 50 of the 92 points we could judge it on, which is 54 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Functional neurology)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1994 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 4 / 7 Cited 41 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.2 citations a year over 34 year(s) since 1994
Impact for its field and year 1 / 6 Cited 0.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Paolo La Commare holds only 8 work(s), too few to judge a track record — left out of this score
Institution's track record 1 / 3 University of Turin: institution h-index 903 (OpenAlex)
Multicenter collaboration 2 / 3 PubMed indexes it as a multicentre study
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 7988944)
Free to read 0 / 2 Behind a paywall — scores zero
Points 50 / 92 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 50 of the 92 points we could judge it on is 54 out of 100.
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →